Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Biomarkers and translational research approaches in breast cancer —an update
SummaryDiagnosis and decision-making in the treatment of breast cancer patients is vastly dependent on the exploration of biomarkers. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor  2 are long-standing biomarkers, which determine the breast cancer subtype. In current practice, gene expression analyses further define the molecular breast cancer subtype and give additional information on disease characteristics. Prognostic biomarkers provide information regarding recurrence ri sk and survival. Predictive biomarkers, such as programmed cell death ligand 1 expression, are tools for ide...
Source: Memo - Magazine of European Medical Oncology - December 12, 2022 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ESMO Hybrid Congress , 9th – 13th September 2022
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research

ASCO update —best of the best
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research

Neuroendocrine neoplasms revisited —the challenges of reclassifying tumor
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research

ASCO update —best of the best
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research

Neuroendocrine neoplasms revisited —the challenges of reclassifying tumor
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2022 Category: Cancer & Oncology Source Type: research

Total neoadjuvant therapy in rectal cancer
SummaryTotal neoadjuvant therapy is a  novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and until now, no overall survival benefit has been reported. This review is a critical, objective summary viewed from different perspectives of the available literature of previous milestones that have been achieved in the treatment of locally advanced rectal cancer, of current recommendations, and of future perspectives. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 30, 2022 Category: Cancer & Oncology Source Type: research

ASCO update: hepatocellular and cholangiocellular carcinoma
SummaryAt ASCO 2022 several studies were presented. This short review is about hepatocellular carcinoma, and cholangiocellular carcinoma and trials like STAMP, ImmunoTACE trial, FOENIX-CCA2, ImmunoTACE trial, for example. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 23, 2022 Category: Cancer & Oncology Source Type: research

Best of ASCO 2022 —central nervous system tumors
SummaryIn this article, updates on novel therapy approaches in central nervous system tumors presented at the ASCO 2022 meeting are summarized. Promising outcome results on targeted therapies in rare entities such as neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors [1] and in v ‑RAF murine sarcoma viral oncogene homolog (BRAF)V600 mutant pediatric glioma are reported [2,3]. Furthermore, we shortly review data on additional administration of polyADP-ribose polymerase (PARP) inhibitor veliparib (Alliance A071102 trial) [4] and on a  combinatorial immunotherapy regime (consisting of intramuscular adminis...
Source: Memo - Magazine of European Medical Oncology - November 5, 2022 Category: Cancer & Oncology Source Type: research

Best of ASCO 2022 —bladder cancer
SummaryAlthough no game-changing studies in bladder cancer were presented this year at ASCO, we saw a  series of interesting data including follow-up updates, exploratory analyses and promising results of phase I/II trials. An up-date analysis of the JAVELIN 100 Bladder study indicated a benefit of avelumab maintenance treatment irrespective of the response to platin-based first-line treatment an d administration of second-line treatment. A new HER2-directed antibody drug conjugate, disitamab vedotin, showed promising results with high-response rates in HER2 high and low bladder cancer. Longer follow-up data confirmed ...
Source: Memo - Magazine of European Medical Oncology - November 2, 2022 Category: Cancer & Oncology Source Type: research

ASCO 2022 update: (neo-)adjuvant treatment of colorectal cancer
SummaryIn this short review, two late breaking abstracts of neoadjuvant and adjuvant treatment concepts for colorectal cancer presented at ASCO 2022 will be highlighted. Both treatment concepts have the potential to change the standard of care in a  subgroup of colorectal cancer patients in the future. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 1, 2022 Category: Cancer & Oncology Source Type: research